Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer

Journal of Endocrinological Investigation

Volumn 33, Issue 2, 2010, Pages 83-87

  Piccardo, A ^a   Arecco, F ^b   Morbelli, S ^a   Bianchi, P ^a   Barbera, F ^a   Finessi, M ^b   Corvisieri, S ^b   Pestarino, E ^a   Foppiani, L ^a   Villavecchia, G ^a   Cabria, M ^a   Orlandi, F ^b  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Disease recurrence; rhTSH testing; Thyroglobulin; Thyroid cancer

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER TISSUE; DIFFERENTIATED THYROID CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEWBORN; PROGNOSIS; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 77951776326     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/bf03346558     Document Type: Article

References (23)

1. Schlumberger M. Papillary and follicular thyroid carcinoma. New Engl J Med 1998, 338: 297-306.
2. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86: 1447-1463 (Pubitemid 32374886)
3. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998, 138: 249-252 (Pubitemid 28154769)
4. Spencer CA, LoPresti JS, Faterni S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999, 9: 435-441
5. Cooper DS, Doherty GM, Haugen BR, et al; The American Thyroid Association Guidelines. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16: 109-142
6. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88: 1433-1441 (Pubitemid 36623351)
7. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006, 154: 787-803. (Pubitemid 43997716)
8. Rosário PW, Borges MA, Fagundes TA, Franco AC, Purisch S. Is stimulation of thyroglobulin (Tg) useful in low risk patients with thyroid carcinoma and undetectable Tg on thyroxine and negative neck ultrasound. Clin Endocrinol (Oxf) 2005, 62: 121-125 (Pubitemid 40203904)
9. Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay during thyroxine treatment in low-risk differetiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med 2006, 44: 648-652 (Pubitemid 43735641)
10. Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008, 93: 76-81.
11. Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999, 26: 1448-1452 (Pubitemid 29515606)
12. Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004, 45: 988-994
13. Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med 2005, 43: 843-847 (Pubitemid 41461160)
14. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005, 90: 1440-1445
15. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002, 94: 2511-2516 (Pubitemid 34457134)
16. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recom-binant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002, 87: 1490-1498
17. Robbins RJ, Chon JT, Fleisher M, Larson S, Turtle RM. Is the serum thyroglobulin response to recombinant human TSH sufficient, by itself, to-monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002, 87: 3242-3247
18. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999, 84: 3877-3885
19. David A, Blotta A, Bondanelli M, et al. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 2001, 42: 1470-5.
20. Vitale G, Lupoli GA, Ciccarelli A, et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf) 2002, 56: 247-252
21. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002, 12: 37-43.
22. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001, 86: 5686-5690
23. Wartofsky L; rhTSH-Stimulated Thyroglobulin Study Group. Management of low-risk well differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. The rhTSH-stimulated Thyroglobulin Study Group. Thyroid 2002, 12: 583-590